524824 Stock Overview
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India, Uzbekistan, Guatemala, and Malta.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Bal Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹117.30 |
| 52 Week High | ₹132.20 |
| 52 Week Low | ₹81.50 |
| Beta | 0.57 |
| 11 Month Change | -0.55% |
| 3 Month Change | 17.09% |
| 1 Year Change | 19.61% |
| 33 Year Change | 23.60% |
| 5 Year Change | 201.54% |
| Change since IPO | 1,061.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524824 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.1% | 2.2% | -1.0% |
| 1Y | 19.6% | 46.7% | 43.6% |
Return vs Industry: 524824 underperformed the Indian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: 524824 underperformed the Indian Market which returned 43.6% over the past year.
Price Volatility
| 524824 volatility | |
|---|---|
| 524824 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 524824 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524824's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 869 | Shailesh Siroya | www.balpharma.com |
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India, Uzbekistan, Guatemala, and Malta. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands.
Bal Pharma Limited Fundamentals Summary
| 524824 fundamental statistics | |
|---|---|
| Market cap | ₹1.84b |
| Earnings (TTM) | ₹73.92m |
| Revenue (TTM) | ₹3.39b |
24.9x
P/E Ratio0.5x
P/S RatioIs 524824 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524824 income statement (TTM) | |
|---|---|
| Revenue | ₹3.39b |
| Cost of Revenue | ₹1.92b |
| Gross Profit | ₹1.47b |
| Other Expenses | ₹1.40b |
| Earnings | ₹73.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 12, 2024
| Earnings per share (EPS) | 4.71 |
| Gross Margin | 43.47% |
| Net Profit Margin | 2.18% |
| Debt/Equity Ratio | 201.6% |
How did 524824 perform over the long term?
See historical performance and comparison